Skip to main content

Indian Pharmaceutical Industry - A plethora of Sustainable Growth Opportunities for pharma business aspirants

 

Clinical courses

Magazine Home


March 2016 ARTICLE LIST >>

PharmaTutor (March- 2016)

 

Print-ISSN: 2394 - 6679
e-ISSN: 2347 - 7881
(Volume 4, Issue 3)

 

Received On: 16/09/2015; Accepted On: 06/10/2015; Published On: 01/03/2016

 

AUTHORS:
Rhit Srivastava* & Saurabh Kumar Banerjee,
School of Pharmaceutical Management,
The IIHMR University, Jaipur, Rajasthan, India
*rhitsrivastava@gmail.com

 

Worldwide the Pharmaceutical industry dynamics is undergoing a significant transformation in terms of cutting edge advancement in the areas of pharmaceutical R&D specially the biotechnology based products, innovative drug delivery technologies, and large scale efficient pharmaceutical manufacturing capacities and so on. According to the list published by FDA for GMP facilities producing generic drug products and APIs for the US market 70% of the APIs and FDFs (Finished dosage Form Facilities) are produced outside US and India counts for 23.7 % of the API and FDF facilities and is by far the largest country exporting to the US. Even China counts for less than a half of the FDF and API facilities exporting to the US, as compared to India [1].

 

How to cite this article: Srivastava R, Banerjee SK; Indian Pharmaceutical Industry - A plethora of Sustainable Growth Opportunities for pharma business aspirants; PharmaTutor; 2016; 4(3); 13-16

 

[ABSTRACT WITH CITATION]   [VIEW AS HTML]